Anlon Healthcare is aggressively expanding capacity and acquiring two companies after its August 2025 IPO. The company aims for 1,400-1,600 MTPA capacity by FY26 and reported strong financial growth in 9M FY26.
Anlon Healthcare Pursues Aggressive Growth Post-IPO
121.32 Cr 9M FY26 Income; 116% YoY Q2 Income Growth Reader Takeaway: Capacity expansion and acquisitions signal growth; execution risk and market volatility are key concerns. ## What just happened Anlon Healthcare Limited, following its August 2025 IPO, is detailing its 2025-26 annual report. The company is focusing on enhancing manufacturing capacity, acquiring majority stakes in Apiqo Organics and Bizotic Lifescience, and growing its Contract Development and Manufacturing Organization (CDMO) business. By the end of FY26, Anlon Healthcare aims to achieve a total manufacturing capacity of 1,400–1,600 MTPA. ## Why this matters These strategic moves signal a significant growth phase for Anlon Healthcare. The capacity expansion and acquisitions are designed to bolster its market position and revenue streams. The company reported strong financial performance, with total income at Rs. 121.32 crore for the first nine months of FY26, a substantial increase from Rs. 71.49 crore in the previous year. In Q2 FY26, income surged 116% year-on-year to Rs. 52.32 crore, with Profit After Tax (PAT) reaching Rs. 9.32 crore. ## The backstory The company successfully raised Rs. 121.03 crore through its IPO in August 2025. It is now moving to acquire 100% equity in Apiqo Organics Private Limited and Bizotic Lifescience Private Limited via a preferential share issuance, a deal valued at up to Rs. 153.30 crore. Anlon is also undertaking a 700 MTPA greenfield expansion, which will increase its total capacity to 1,100 MTPA, with further plans to reach 1,400–1,600 MTPA by FY26. ## What changes now The company's operational capacity is set to significantly increase. Its Anvisa-approved facility, with zero observations, enhances its export potential. Management is targeting a 30%+ revenue CAGR over the next three years and aims to maintain EBITDA margins between 25–30%, leveraging global 'China Plus One' strategies and focusing on complex generics and CDMO services. ## Risks to watch Key risks include the successful execution of its large-scale capacity expansion and the integration of the newly acquired companies. Management also noted challenges in the global generic market during the last quarter of FY26, citing geopolitical uncertainty, tariff threats, and supply chain disruptions as significant concerns. ## Peer comparison While specific peer financials are not detailed in the filing, Anlon's move into CDMO operations and capacity expansion aligns with industry trends focused on reliable manufacturing bases outside of China. ## Context metrics (time-bound) * **9M FY26 Total Income:** Rs. 121.32 crore (vs. Rs. 71.49 crore previous year). * **Q2 FY26 Total Income:** Rs. 52.32 crore (up 116% YoY). * **Q2 FY26 PAT:** Rs. 9.32 crore. * **IPO Raised:** Rs. 121.03 crore (August 2025). * **Acquisition Consideration:** Not exceeding Rs. 153.30 crore. * **Target Capacity FY26:** 1,400–1,600 MTPA. ## What to track next Investors will be closely watching the progress of the AOPL and BLPL integration, the scaling of manufacturing capacity, and the company's ability to sustain its targeted margins amidst global market volatility.
